Pulmonx Corporation updated its revenue guidance for fiscal year 2023. For the period, the company is increasing its expectation to now range from $64 million to $66 million, which represents approximately 19% to 23% growth over the Company's fiscal year 2022 revenue. This updated guidance compares to prior 2023 revenue guidance of $63 million to $65 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.83 USD | +1.04% |
|
-13.53% | -53.88% |
Jun. 04 | Lake Street Initiates Pulmonx With Buy Rating, $12 Price Target | MT |
May. 01 | Earnings Flash (LUNG) PULMONX CORPORATION Posts Q1 Revenue $18.9M, vs. Street Est of $17.9M | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.88% | 224M | |
+75.67% | 12.57B | |
-26.44% | 7.28B | |
+14.52% | 5.47B | |
-20.49% | 4.73B | |
+14.91% | 4.09B | |
-23.83% | 3.78B | |
-31.85% | 2.63B | |
+38.31% | 2.3B | |
-0.87% | 2.03B |
- Stock Market
- Equities
- LUNG Stock
- News Pulmonx Corporation
- Pulmonx Corporation Updates Revenue Guidance for Fiscal Year 2023